06978.HK
Immunotech Biopharm Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 0.40
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 49.8M | 53.9M | — | — | — |
| Gross Profit | (49.8M) | (53.9M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 206.3M | 85.4M | 154.2M | 177.3M | 69.8M |
| SG&A Expense | 70.6M | 41.0M | 44.5M | 53.2M | 97.7M |
| General & Admin Expense | 41.1M | 41.0M | 44.5M | 53.2M | 97.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (10.9M) | — | — | 106.5M |
| Total Operating Expenses | 276.9M | 115.5M | 198.8M | 230.5M | 273.9M |
| Cost and Expenses | 326.7M | 155.8M | 198.8M | 230.5M | 273.9M |
| Operating Income (EBIT) | (326.7M) | (155.8M) | (198.8M) | (230.5M) | (273.9M) |
| Non-Operating | |||||
| Interest Income | 1.4M | 518.2K | 1.1M | 5.5M | 3.2M |
| Interest Expense | 30.2M | 6.6M | 6.4M | — | 6.1M |
| Net Interest Income | (29.9M) | (6.1M) | (6.4M) | (5.5M) | (2.9M) |
| Other Non-Op Income/Expense | (65.2M) | (75.1M) | 12.4M | (104.9M) | (47.2M) |
| Non-Operating Income (excl Interest) | 1.8M | 68.3M | 2.1M | 500.0K | 288.0K |
| EBT (Pre-Tax Income) | (392.0M) | (230.9M) | (186.4M) | (335.5M) | (321.1M) |
| Income Tax Expense | 928.0K | — | 926.0K | — | 31.7M |
| Bottom Line | |||||
| Net Income | (392.4M) | (230.8M) | (186.9M) | (334.8M) | (318.1M) |
| Earnings from Cont. Ops | (392.9M) | (230.9M) | (187.3M) | (335.5M) | (321.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (392.4M) | (224.8M) | (186.9M) | (334.8M) | (318.1M) |
| Per Share | |||||
| Basic EPS | (HK$0.71) | (HK$0.42) | (HK$0.36) | (HK$0.65) | (HK$0.62) |
| Diluted EPS | (HK$0.71) | (HK$0.42) | (HK$0.36) | (HK$0.65) | (HK$0.62) |
| Revenue Per Share | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 617.5M | 549.0M | 514.6M | 514.6M | 514.6M |
| Diluted Shares Outstanding | 617.5M | 549.0M | 514.6M | 514.6M | 514.6M |
| Profitability Metrics | |||||
| EBITDA | (227.2M) | (168.8M) | (148.7M) | (178.8M) | (231.1M) |
| D&A | 101.3M | 55.3M | 52.2M | 52.2M | 43.1M |
| EBIT | (328.5M) | (224.1M) | (200.9M) | (231.0M) | (274.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026